Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS

Key Points

• Kornitzer Capital Management trimmed its stake by 53.1%, selling 12,575 shares and leaving 11,114 Alnylam shares worth about $4.42M, while institutional investors and hedge funds own roughly 92.97% of the stock.
• Insiders sold 38,656 shares (~$12.37M) in the last quarter (notably EVPs Pushkal Garg and Kevin Fitzgerald), reducing insider ownership to about 0.86%.
• Alnylam beat Q1 estimates with EPS of $1.99 vs. $0.90 expected and revenue of $1.17B vs. $1.12B, fueled by roughly 187% growth in Amvuttra sales and 96% year‑over‑year revenue growth.

Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 53.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 11,114 shares of the biopharmaceutical company's stock after selling 12,575 shares during the period. Kornitzer Capital Management Inc. KS's holdings in Alnylam Pharmaceuticals were worth $4,419,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Mediolanum International Funds Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $11,389,000. Rakuten Investment Management Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $14,205,000. Generali Asset Management SPA SGR grew its position in shares of Alnylam Pharmaceuticals by 6,368.0% during the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company's stock worth $1,475,000 after purchasing an additional 3,184 shares in the last quarter. Cerity Partners LLC grew its position in shares of Alnylam Pharmaceuticals by 171.2% during the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company's stock worth $12,507,000 after purchasing an additional 17,316 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $5,790,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president directly owned 24,848 shares in the company, valued at $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total transaction of $677,530.36. Following the sale, the executive vice president owned 21,264 shares of the company's stock, valued at approximately $7,058,797.44. This trade represents a 8.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 38,656 shares of company stock valued at $12,370,696 in the last quarter. Insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $296.11 on Friday. The company has a market cap of $39.51 billion, a price-to-earnings ratio of 80.90 and a beta of 0.31. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The firm has a 50 day simple moving average of $320.11 and a 200 day simple moving average of $376.83. Alnylam Pharmaceuticals, Inc. has a one year low of $245.96 and a one year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.90 by $1.09. The business had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 118.63%. The firm's revenue was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.44) EPS. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year‑over‑year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re‑rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ALNY. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an "outperform" rating for the company in a report on Friday. Freedom Capital raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Tuesday, February 17th. Chardan Capital reaffirmed a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Jefferies Financial Group reaffirmed a "hold" rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Finally, Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a "buy" rating in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $471.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.